NCT02876107View on ClinicalTrials.gov

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 6, 2016

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Breast CarcinomaBreast LumpEdemaErythemaEstrogen Receptor NegativeHER2/Neu NegativeInflammatory Breast CarcinomaInvasive Breast CarcinomaPeau d'OrangeProgesterone Receptor NegativeTriple-Negative Breast Carcinoma
Interventions
DRUG

Carboplatin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Paclitaxel

Given IV

BIOLOGICAL

Panitumumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Amgen

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02876107 - Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter